MarketCatalyst
← Back to Resources
Earnings

Legend Biotech Q3 2026 EPS Tops Estimates at $0.14, but Revenue Misses at $359.5M

Revenue of $359.5M vs. $361.5M expected and adjusted EPS of $0.14 vs. $0.01; revenue up 32% from a year earlier.

Published Nov 10, 2026 · 7:02 AM ET · 2 min read

Legend Biotech (LEGN) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $359.5 million, up 32% from a year earlier, below the $361.5 million estimate, and adjusted EPS was $0.14 above the $0.01 estimate.

Shares fell 2.8% in premarket trading as of 6:58 a.m. ET, to $23.60 from a $24.29 close.

$0.14
Adjusted EPS vs. $0.01 estimate
$359.5M
Revenue, up 32% YoY vs. $361.5M estimate
-2.8%
Shares premarket as of 6:58 a.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS$0.01$0.14Beat by 1300%
Revenue$361.5M$359.5MMiss by 0.5%
ChangeYoYQoQ
Adjusted EPS▲ from -$0.11▲ 56%
Revenue▲ 32%▼ 7.2%

By our calculation, revenue was $2.0 million below the estimate and adjusted EPS was $0.13 above it. The QoQ column compares with the previous quarter's revenue of $387.5 million and adjusted EPS of $0.09. The YoY column compares with $272.3 million and -$0.11 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 5 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 4 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $272.3 million, $306.3 million, $305.1 million, $387.5 million and $359.5 million.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of $0.03 and revenue of $386.0 million next quarter, based on 3 analysts.
  • Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 32% increase to $359.5 million.
  • Estimate record. Whether Legend Biotech extends a record of beating EPS estimates in 5 of its last 8 reports.
  • Related coverage. See our reports on Alliance Laundry, Sally Beauty, Sea and TransDigm.

Sources: Results are from Legend Biotech's Nov. 10, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Legend Biotech's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.